Larimar Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Larimar Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Mar 5, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Mar 5, 2020 |
| FY2019 | Jun 30, 2019 | $0 | Mar 5, 2020 |
| FY2019 | Mar 31, 2019 | $0 | Mar 5, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 5, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Mar 5, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Mar 5, 2020 |
| FY2019 | Mar 31, 2018 | $0 | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Mar 14, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($165.67M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($80.60M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($36.95M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($35.36M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($50.64M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($42.48M) | Mar 25, 2022 |
| FY2019 | Dec 31, 2019 | ($7.25M) | Mar 5, 2020 |
| FY2019 | Sep 30, 2019 | ($12.91M) | Mar 5, 2020 |
| FY2019 | Jun 30, 2019 | ($12.13M) | Mar 5, 2020 |
| FY2019 | Mar 31, 2019 | ($13.11M) | Mar 5, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($172.50M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($90.89M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($41.76M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($36.53M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($50.47M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($42.80M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($23.21M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($61.12M) | Mar 5, 2020 |
| FY2019 | Dec 31, 2017 | ($53.00M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | ($58.23M) | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.22M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $73.28M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $27.67M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $24.25M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $38.40M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $31.41M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $20.79M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $47.93M | Mar 5, 2020 |
| FY2019 | Dec 31, 2017 | $40.84M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $39.94M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.20M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($70.76M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($33.46M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($27.57M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($42.11M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($42.20M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($22.70M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($51.49M) | Mar 5, 2020 |
| FY2019 | Dec 31, 2017 | ($43.78M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | ($51.98M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $515.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $164.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $100.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $333.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $62.0K | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $83.0K | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $108.0K | Mar 5, 2020 |
| FY2019 | Dec 31, 2017 | $55.0K | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $660.0K | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.84M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $200.23M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $95.94M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $126.41M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $78.67M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $104.69M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.20M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $121.76M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $105.51M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $131.62M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.76M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $28.41M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $14.22M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $15.50M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $14.25M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $14.99M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.90M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $28.49M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $27.29M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $9.89M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.09M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $171.81M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $81.72M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $110.90M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $64.41M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $89.69M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($694.0K) | Mar 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.91M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $78.22M | Mar 5, 2020 |
| FY2019 | Dec 31, 2016 | $121.73M | Mar 5, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($434.83M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($269.16M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($188.55M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($151.61M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($116.25M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($65.61M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($23.13M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($350.95M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($289.58M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($237.55M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.41M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $33.22M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $26.75M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $26.83M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $70.10M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $68.15M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.01M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $49.33M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $40.78M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $32.35M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $14.55M | Mar 5, 2020 |
| FY2018 | Dec 31, 2018 | $20.00M | Mar 14, 2019 |
| FY2017 | Dec 31, 2017 | $20.00M | Mar 9, 2018 |
| FY2016 | Dec 31, 2016 | $3.18M | Mar 10, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.09M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 63.82M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 43.91M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 43.27M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 17.71M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 15.37M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | 6.09M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 37.29M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 27.49M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 27.33M | Mar 9, 2018 |